Ma ka lā 1 o Mei, 2025, ua hoʻolaha ʻo Hansoh Pharmaceutical ua loaʻa i ka hui ponoʻī ʻo B7-H4-targeted antibody-drug conjugate (ADC) HS-20089 no ka injection i ka ʻae ʻia e hoʻokomo ʻia ma ke ʻano he Breakthrough-Therapy-Designated Drug e ka National Medical Products Administration (NMPA) o Kina, me ka hōʻailona i manaʻo ʻia no ka maʻi ʻaʻai epithelial ovarian recurrent platinum-resistant, ka maʻi ʻaʻai tube fallopian a i ʻole nā maʻi ʻaʻai peritoneal mua.
Ua kākoʻo ʻia ke koho ʻana e nā hopena mai ke aʻo ʻana o ka Phase I HS-20089-101 a me ke aʻo ʻana o ka Phase II HS-20089-201. ʻO ke aʻo ʻana o HS-20089-101 he hoʻokolohua lapaʻau Phase I multi-center, open-label e loiloi i ka palekana, ka hiki ke hoʻomanawanui, ka pharmacokinetics, a me ka pono o HS-20089 no ka injection i nā poʻe maʻi me nā puʻupuʻu paʻa holomua. ʻO ke aʻo ʻana o HS-20089-201 he hoʻokolohua lapaʻau Phase II multi-center, open-label e loiloi i ka pono, ka palekana, ka ʻikepili pharmacokinetic, a me ka immunogenicity o ka intravenous HS-20089 i nā poʻe maʻi me ka maʻi ʻaʻai ovarian recurrent a metastatic paha a me ka maʻi ʻaʻai endometrial.
ʻO HS-20089 kahi ADC i hoʻolālā ʻia no B7-H4 me kahi ukana topoisomerase inhibitor (TOPOi) e hoʻomohala ʻia nei no ka mālama ʻana i ka maʻi ʻaʻai ovarian a me nā puʻupuʻu gynecological ʻē aʻe i nā hoʻokolohua lapaʻau he nui ma Kina, me ke kahua noiʻi kiʻekiʻe loa ʻo ia nā hoʻokolohua lapaʻau Phase III. ʻO B7-H4 kahi glycoprotein transmembrane immune checkpoint i hōʻike nui ʻia i loko o nā puʻupuʻu paʻa he nui, me ke kanesa endometrial a me ke kanesa ovarian, akā me ka palena o ka hōʻike ʻana i nā ʻiʻo maʻamau.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Leka uila:myimmnet@163.com
Ka manawa hoʻouna: Mei-09-2025